In the past week, APLS stock has gone up by 10.47%, with a monthly gain of 7.89% and a quarterly plunge of -6.51%. The volatility ratio for the week is 4.16%, and the volatility levels for the last 30 days are 5.74% for Apellis Pharmaceuticals Inc The simple moving average for the past 20 days is 6.93% for APLS’s stock, with a -22.35% simple moving average for the past 200 days.
Is It Worth Investing in Apellis Pharmaceuticals Inc (NASDAQ: APLS) Right Now?
APLS has 36-month beta value of 0.88. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for APLS is 100.86M, and currently, short sellers hold a 15.78% ratio of that float. The average trading volume of APLS on August 21, 2024 was 1.48M shares.
APLS) stock’s latest price update
The stock of Apellis Pharmaceuticals Inc (NASDAQ: APLS) has increased by 2.16 when compared to last closing price of 38.95.Despite this, the company has seen a gain of 10.47% in its stock price over the last five trading days. investorplace.com reported 2024-08-13 that Investment bank Wedbush may be best-known for its sell-side coverage of high-profile tech stocks like Tesla (NASDAQ: TSLA ), but taking a look at the new Wedbush price targets, you’ll find that the EV maker is not on this list. Neither are many of the other well-known names in tech.
Analysts’ Opinion of APLS
Many brokerage firms have already submitted their reports for APLS stocks, with Piper Sandler repeating the rating for APLS by listing it as a “Neutral.” The predicted price for APLS in the upcoming period, according to Piper Sandler is $46 based on the research report published on May 31, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see APLS reach a price target of $80, previously predicting the price at $68. The rating they have provided for APLS stocks is “Buy” according to the report published on February 05th, 2024.
APLS Trading at 3.79% from the 50-Day Moving Average
After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.08% of loss for the given period.
Volatility was left at 5.74%, however, over the last 30 days, the volatility rate increased by 4.16%, as shares surge +6.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.56% lower at present.
During the last 5 trading sessions, APLS rose by +10.49%, which changed the moving average for the period of 200-days by -19.30% in comparison to the 20-day moving average, which settled at $37.33. In addition, Apellis Pharmaceuticals Inc saw -33.53% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLS starting from Dunlop A. Sinclair, who sale 37,000 shares at the price of $39.24 back on Jun 21 ’24. After this action, Dunlop A. Sinclair now owns 136,998 shares of Apellis Pharmaceuticals Inc, valued at $1,451,835 using the latest closing price.
Deschatelets Pascal, the Chief Scientific Officer of Apellis Pharmaceuticals Inc, sale 78,907 shares at $42.35 during a trade that took place back on May 08 ’24, which means that Deschatelets Pascal is holding 1,115,983 shares at $3,341,848 based on the most recent closing price.
Stock Fundamentals for APLS
Current profitability levels for the company are sitting at:
- -0.53 for the present operating margin
- 0.86 for the gross margin
The net margin for Apellis Pharmaceuticals Inc stands at -0.54. The total capital return value is set at -0.44. Equity return is now at value -109.19, with -36.58 for asset returns.
Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 1.75. The interest coverage ratio of the stock is 141.02.
Currently, EBITDA for the company is -515.42 million with net debt to EBITDA at -0.35. When we switch over and look at the enterprise to sales, we see a ratio of 8.11. The receivables turnover for the company is 2.0for trailing twelve months and the total asset turnover is 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.08.
Conclusion
To put it simply, Apellis Pharmaceuticals Inc (APLS) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
